書籍詳細

座談会

P.8 掲載の参考文献

• 1) Kazama JJ : Bone 45 (Suppl 1), S8-12, 2009
  pubmed

• 2) Yokoyama K, et al : J Ren Nutr 24 (4), 261-267, 2014

• 3) Matsumura K : Yakugaku Zasshl 135 (4), 545-549, 2015

• 4) Karaboyas A, et al : Clin J Am Soc Nephrol 10 (10), 1814-1821, 2015

• 5) Coe LM, et al : J Biol Chem 289 (14), 9795-9810, 2014

• 6) Yokoyama K, et al : Clln J Am Soc Nephrol 9 (3), 543-552, 2014

• 7) David V, et al : Kldney Int 89 (1), 135-146, 2016
  pubmed

• 8) Iguchi A, et al : Nephron 131 (3), 161-166, 2015
  pubmed

• 9) Keryx Biopharmaceuticais社 HP : http://keryx.com/

• 10) Tanaka M, et al : Biol Pharm Bull 2016, in press

• 11) 宮崎章他 : 日薬理誌 144 (6), 294-304, 2014

• 12) 日本医師会 : 平成25年度 (第47回) 臨床検査精度管理調査結果報告書

特集 クエン酸第二鉄Dual Therapyへの期待と展望

P.15 掲載の参考文献

• 1) Nishida Y, Taketani Y, Yamanaka-Okumura H, et al : Acute effect of oral phosphate loading on serum fibroblast growth factor 23 levels in healthy men. Kidney Int 70 : 2141-2147, 2006
  pubmed

• 2) Isakova T, Wahl P, Vargas GS, et al : Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 79 : 1370-1378, 2011

• 3) Marks J, Debnam ES, Unwin RJ : Phosphate homeostasis and the renal-gastrointestinal axis. Am J Physiol Renal Physiol 299 : F285-296, 2010
  pubmed

• 4) Heaf JG, Nielsen LP : Serum aluminium in haemodialysis patients : relation to osteodystrophy, encephalopathy and aluminium hydroxide consumption. Miner Electrolyte Metab 10 : 345-350, 1984
  pubmed

• 5) Alfrey AC, LeGendre GR, Kaehny WD : The dialysis encephalopathy syndrome. Possible aluminum intoxication. N Engl J Med 294 : 184-188, 1976

• 6) de Francisco AL, Leidig M, Covic AC, et al : Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients : a controlled randomized study (CALMAG study) assessing effcacy and tolerability. Nephrol Dial Transplant 25 : 3707-3717, 2010

• 7) Slatopolsky E, Weerts C, Lopez-Hilker S, et al : Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis. N Engl J Med 315 : 157-161, 1986

• 8) Shroff RC, McNair R, Skepper JN, et al : Chronic mineral dysregulation promotes vascular smooth muscle cell adaptation and extracellular matrix calcification. J Am Soc Nephrol 21 : 103-112, 2010
  pubmed

• 9) Jamal SA, Vandermeer B, Raggi P, et al : Effect of calcium-based versus non-calciumbased phosphate binders on mortality in patients with chronic kidney disease : an updated systematic review and meta-analysis. Lancet 382 : 1268-1277, 2013

• 10) 日本透析医学会 : 慢性腎臓病に伴う骨・ミネラル代謝異常の診療ガイドライン. 透析会誌 45 : 301-356, 2012

• 11) Rastogi A : Sevelamer revisited : pleiotropic effects on endothelial and cardiovascular risk factors in chronic kidney disease and end-stage renal disease. Ther Adv Cardiovasc Dis 7 : 322-342, 2013

• 12) Komaba H, Kakuta T, Suzuki H, et al : Survival advantage of lanthanum carbonate for hemodialysis patients with uncontrolled hyperphosphatemia. Nephrol Dial Transplant 30 : 107-114, 2015
  pubmed

• 13) Makino M, Kawaguchi K, Shimojo H, et al : Extensive lanthanum deposition in the gastric mucosa : the first histopathological report. Pathol Int 65 : 33-37, 2015
  pubmed

• 14) Block GA, Wheeler DC, Persky MS, et al : Effects of phosphate binders in moderate CKD. J Am Soc Nephrol 23 : 1407-1415, 2012

• 15) Hilfiker H, Hattenhauer O, Traebert M, et al : Characterization of a murine type II sodium-phosphate cotransporter expressed in mammalian small intestine. Proc Natl Acad Sci USA 95 : 14564-14569, 1998

• 16) Sabbagh Y, O'Brien SP, Song W, et al : Intestinal npt2b plays a major role in phosphate absorption and homeostasis. J Am Soc Nephrol 20 : 2348-2358, 2009

• 17) Katai K, Tanaka H, Tatsumi S, et al : Nicotinamide inhibits sodium-dependent phosphate cotransport activity in rat small intestine. Nephrol Dial Transplant 14 : 1195-1201, 1999

• 18) Eto N, Miyata Y, Ohno H, et al : Nicotinamide prevents the development of hyperphosphataemia by suppressing intestinal sodium-dependent phosphate transporter in rats with adenine-induced renal failure. Nephrol Dial Transplant 20 : 1378-1384, 2005
  pubmed

• 19) Nomura K, Tatsumi S, Miyagawa A, et al : Hepatectomy-related hypophosphatemia : a novel phosphaturic factor in the liver-kidney axis. J Am Soc Nephrol 25 : 761-772, 2014

P.21 掲載の参考文献

• 1) Kazama JJ : Oral phosphate binders : history and prospects. Bone 45 : S8-12, 2009
  pubmed

• 2) Yokoyama K, Hirakata H, Akiba T, et al : Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD. Clin J Am Soc Nephrol 9 : 543-552, 2014

• 3) Iguchi A, Kazama JJ, Yamamoto S, et al : Administration of Ferric Citrate Hydrate Decreases Circulating FGF23 Levels Independently of Serum Phosphate Levels in Hemodialysis Patients with Iron Deficiency. Nephron 131 : 161-166, 2015

• 4) Haratake J, Yasunaga C, Ootani A, et al : Peculiar histiocytic lesions with massive lanthanum deposition in dialysis patients treated with lanthanum carbonate. Am J Surg Pathol 39 : 767-771, 2015

• 5) Floege J, Covic AC, Ketteler M, et al : Sucroferric Oxyhydroxide Study Group. Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients. Nephrol Dial Transplant 30 : 1037-1046, 2015

P.28 掲載の参考文献

• 1) 小山純一, 山根省吾, 塩田幸雄他 : 新規高リン血症治療剤リオナ錠250mg(R) の製剤特性. 臨床透析 31 : 1543-1549, 2015

• 2) 永野伸郎, 福島直 : 慢性腎不全患者の高リン血症に対する新規リン結合性ポリマー (塩酸セベラマー) の薬理作用ならびに臨床試験成績. 日薬理誌 122 : 443-453, 2003
  Medical*Online

• 3) 吉本宏, 永野伸郎, 西鳥羽剛, 他 : 新規経口吸着剤キトサン被覆酸化セルロースの薬理学的特性 (第1報) 正常ラットに対する作用. 日薬理誌 106 : 113-122, 1995

• 4) 日本たばこ産業株式会社 : JTT-751第II相臨床試験-血液透析患者を対象としたJTT-751の有効性及び安全性についての検討- (GBA2-1). 日本たばこ産業株式会社社内資料

• 5) 山田耕嗣, 田中新樹 : 高リン血症を呈したPPI服用患者群におけるクエン酸第二鉄水和物の治療検討. 透析会誌 48 (Suppl 1) : 660, 2015

• 6) 吉田宗弘, 柴田美由起 : 炭酸ランタンが病院一般食に含有されるリンのbioaccessibilityに及ぼす影響. Biomed Res Trace Elements 22 : 130, 2011
  Medical*Online

• 7) 末廣剛敏, 矢毛石陽一, 實藤健作, 他 : 慢性腎不全維持透析患者の胃粘膜傷害の現状と対策. 臨牀と研究 86 : 1033-1037, 2009
  Medical*Online

P.38 掲載の参考文献

• 1) de Francisco AL : Secondary hyperparathyroidism : review of the disease and its treatment. Clin Ther 26 : 1976-1993, 2004
  pubmed

• 2) Kalantar-Zadeh K, Kuwae N, Rejidor DL, et al : Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 70 : 771-780, 2006

• 3) Shigematsu T, Kono T, Satoh K, et al : Phosphate overload accelerates vascular calcium deposition in end-stage renal disease patients. Nephrol Dial Transplant 18 : iii86-iii89, 2003
  pubmed

• 4) Slatopolsky E, Brown A, Dusso A, et al : Pathogenesis of secondary hyperparathyroidism. Kidney Int Suppl 73 : S14-S19, 1999
  pubmed

• 5) 日本透析医学会 : 慢性腎臓病に伴う骨・ミネラル代謝異常の診療ガイドライン. 日透析医学会誌 45 : 301-356, 2012

• 6) Cox G, Dodds M, Wigman H, et al : The effects of high doses of aluminium and iron on phosphorus metabolism. J Biol Chem 92 : Xi-Xii, 1931

• 7) 宮崎章, 松尾明, 飯田聡夫, 他 : 新規高リン血症治療薬クエン酸第二鉄水和物 (リオナ(R) 錠250mg) の薬理学的特性と臨床試験成績. 日薬理誌 (Folia Pharmacol. Jpn.) 144 : 294-304, 2014

• 8) 小山純一, 山根省吾, 塩田幸雄他 : 新規高リン血症治療剤リオナC(R) 錠250mgの製剤特性. 臨牀透析 31 : 1543-1549, 2015

• 9) Iida A, Kemmochi Y, Kakimoto K, et al : Ferric citrate hydrate, a new phosphate binder, prevents the complications of secondary hyperparathyroidism and vascular calcification. Am J Nephrol 37 : 346-358, 2013
  pubmed

• 10) Katsumata K, Kusano K, Hirata M, et al : Sevelamer hydrochloride prevents ectopic calcification and renal osteodystrophy in chronic renal failure rats. Kidney Int 64 : 441-450, 2003

• 11) Yokoyama K, Akiba T, Fukagawa M, et al : Long-Term Safety and Efficacy of a Novel Iron-Containing Phosphate Binder, JTT-751, in Patients Receiving Hemodialysis. J Ren Nutr 24 : 261-267, 2014

• 12) Vaziri ND : Understanding iron : promoting its safe use in patients with chronic kidney failure treated by hemodialysis. Am J Kidney Dis 61 : 992-1000, 2013

• 13) Agarwal R, Vasavada N, Sachs NG, et al : Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int 65 : 2279-2289, 2004
  pubmed

• 14) Yokoyama K, Hirakata H, Akiba T, et al : Effect of oral JTT-751 (ferric citrate) on hyperphosphatemia in hemodialysis patients : results of a randomized, double-blind, placebo-controlled trial. Am J Nephrol 36 : 478-487, 2012

• 15) Yokoyama K, Akiba T, Fukagawa M, et al : A randomized trial of JTT-751 versus sevelamer hydrochloride in patients on hemodialysis. Nephrol Dial Transplant 29 : 1053-1060, 2014
  pubmed

• 16) Yokoyama K, Hirakata H, Akiba T, et al : Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD. Clin J Am Soc Nephrol 9 : 543-552, 2014

• 17) Scialla JJ, Wolf M : Roles of phosphate and fibroblast growth factor 23 in cardiovascular disease. Nat Rev Nephrol 10 : 268-278, 2014
  pubmed

• 18) Block GA, Wheeler DC, Persky MS, et al : Effects of phosphate binders in moderate CKD. J Am Soc Nephrol 23 : 1407-1415, 2012

• 19) Wolf M, Koch TA, Bregman DB : Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. J Bone Miner Res 28 : 1793-1803, 2013
  pubmed

• 20) Iguchi A, Kazama JJ, Yamamoto S, et al : Administration of Ferric Citrate Hydrate Decreases Circulating FGF23 Levels Independently of Serum Phosphate Levels in Hemodialysis Patients with Iron Deficiency. Nephron 131 : 161-166, 2015

• 21) Wolf M, White KE : Coupling fibroblast growth factor 23 production and cleavage : iron deficiency, rickets, and kidney disease. Curr Opin Nephrol Hypertens 23 : 411-419, 2014

• 22) Takeda Y, Komaba H, Goto S, et al : Effect of intravenous saccharated ferric oxide on serum FGF23 and mineral metabolism in hemodialysis patients. Am J Nephrol 33 : 421-426, 2011

• 23) Deger SM, Erten Y, Pasaoglu OT, et al : The effects of iron on FGF23-mediated Ca-P metabolism in CKD patients. Clin Exp Nephrol 17 : 416-423, 2013

P.48 掲載の参考文献

• 1) Jamal SA, Vandermeer B, Raggi P, et al : Effect of calcium-based versus non-calciumbased phosphate binders on mortality in patients with chronic kidney disease : an updated systematic review and meta-analysis. Lancet 382 : 1268-1277, 2013

• 2) 鈴木敦子, 大山康子, 瀬在丸せつこ, 他 : 塩酸セベラマーの適正な使用方法. 透析会誌 37 : 1008, 2004

• 3) 龍田浩一, 重松隆 : 慢性腎臓病におけるリン管理 IX. 新しいリン吸着剤 : 炭酸ランタン 2. 炭酸ランタンの国内外の臨床成績. Clin Calcium 19 : 219-223, 2009

• 4) Code of Federal Regulations : Title 21, Part 184 Direct Food Substances Affirmed as Generally Recognized as Safe, Section 184. 1298 (Ferric citrate). http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?c=ecfr&sid=9447f82d8b983305ff31235ae4d91621&rgn=div8&view=text&node=21 : 3.0.1.1.14.2.1.75&idno=21

• 5) Yang WC, Yang CS, Hou CC, et al : An open-label, crossover study of a new phosphate-binding agent in haemodialysis patients : ferric citrate. Nephrol Dial Transplant 17 : 265-270, 2002
  pubmed

• 6) Yokoyama K, Hirakata H, Akiba T, et al : Effect of oral JTT-751 (ferric citrate) on hyperphosphatemia in hemodialysis patients : results of a randomized, doubleblind, placebo-controlled trial. Am J Nephrol 36 : 478-487, 2012

• 7) Yokoyama K, Akiba T, Fukagawa M, et al : Long-term safety and efficacy of a novel iron-containing Phosphate binder, JTT-751, in patients receiving hemodialysis. J Ren Nutr 24 : 261-267, 2014
  pubmed

• 8) Yokoyama K, Akiba T, Fukagawa M, et al : A randomized trial of JTT-751 versus sevelamer hydrochloride in patients on hemodialysis. Nephrol Dial Transplant 29 : 1053-1060, 2014
  pubmed

• 9) Yokoyama K, Akiba T, Fukagawa M, et al : JTT-751 for treatment of patients with hyperphosphatemia on peritoneal dialysis. Nephron Clin Pract 128 : 135-140, 2014
  pubmed

• 10) Yokoyama K, Hirakata H, Akiba T, et al : Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD. Clin J Am Soc Nephrol 3 : 543-552, 2014

• 11) Hasuike Y, Nonoguchi H, Tokuyama M, et al : Serum ferritin predicts prognosis in hemodialysis patients : the Nishinomiya study. Clin Exp Nephrol 14 : 349-355, 2010
  pubmed

• 12) Kalantar-Zadeh K, Regidor DL, McAllister CJ, et al : Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol 16 : 3070-3080, 2005
  pubmed

• 13) Anker SD, Comin Colet J, FilipPatos G, et al : Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 361 : 2436-2448, 2009

• 14) Block GA, Wheeler DC, Persky MS, et al : Effects of phosphate binders in moderate CKD. J Am Soc Nephrol 23 : 1407-1415, 2012

• 15) Takeda Y, Komaba H, Goto S, et al : Effect of intravenous saccharated ferric oxide on hemodialysis patients. Am J Nephrol 33 : 421-426, 2011

• 16) Wolf M, Koch TA, Bregman DB : Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. J Bone Miner Res 28 : 1793-1803, 2013
  pubmed

• 17) Wolf M, White KE : Coupling fibroblast growth factor 23 production and cleavage : iron deficiency, rickets, and kidney disease. Curr Opin Nephrol Hypertens 23 : 411-419, 2014

• 18) Block GA, Fishbane S, Rodriguez M, et al : A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD Stages 3-5. Am J Kidney Dis 65 : 728-736, 2015

P.53 掲載の参考文献

• 1) 長場泰, 村野順也, 鎌田真理子, 他 : 透析導入期におけるクエン酸第二鉄水和物 (リオナ) のリン管理および貧血に対する臨床効果. 新薬と臨床 64 : 13-19, 2015

• 2) KDIGO Anemia Work Group : KDIGO clinical practice guideline for anemia in CKD. Kidney Int Supple 2 : S279-335, 2012

• 3) Akizawa T, Saito A, Gejyo F, et al : Impacts of Recombinant Human Erythropoetin Treatment During Predialysisi Periods on the Progression of Chronic Kidney Disease in Large-Scale Cohort Study (Co-JET study). Ther Apher Dial 18 : 140-148, 2014

• 4) Kida A, Kuragano T, Furuta M, et al : Hemodialysis restored iron distribution that was sequestered in the spleen by bilateral nephrectomy. Am J physiol Renal Physiol 306 : F1393-1399, 2014
  pubmed

• 5) Yokoyama K, Akiba T, Fukagawa M, et al : A randomized trial of JTT-751 versus sevelamer hydrochloride in patients on hemodialysis. Nephrol Dial Transplant 29 : 1053-1060, 2014
  pubmed

• 6) Deger SM, Erten Y, Pasaoglu OT, et al : The effects of Iron on FGF23-mediated Ca-P metabolism in CKD patients. Clin Exp Nephrol 17 : 416-423, 2013

P.58 掲載の参考文献

• 1) Giachelli CM : Vascular calcification mechanisms. J Am Soc Nephrol 15 : 2959-2964, 2004

• 2) Isakova T, Guti6rrez OM, Chang Y, et al : Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol 20 : 388-396, 2009

• 3) Block GA, Raggi P, Bellasi A, et al : Mortality ef〔ect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 71 : 438-441, 2007

• 4) Kalantar-Zadeh K, Streja E, Miller JE, et al : Intravenous iron versus erythropoiesis-stimulating agents : friends or foes in treating chronic kidney disease anemia? Adv Chronic Kidney Dis 16 : 143-151, 2009

• 5) Anker SD, Comin Colet J, Filippatos G, et al : Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 361 : 2436-2448, 2009
  pubmed

P.67 掲載の参考文献

• 1) 日本透析医学会統計調査委員会 : 図説わが国の慢性透析療法の現況2012年12月31日現在. 東京 : 日本透析医学会, 2013

• 2) Tielemans CL, Lenclud CM, Wens R, et al : Critical role of iron overload in the increased susceptibility of haemodialysis patients to bacterial infections. Beneficial effects of desferrioxamine. Nephrol Dial Transplant 4 : 883-887, 1989
  pubmed

• 3) DrUeke T, Witko-Sarsat V, Massy Z, et al : Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation 106 : 2212-2217, 2002

• 4) 宮崎章, 松尾明, 飯田聡夫, 他 : 新規高リン血症治療薬クエン酸第二鉄水和物 (リオナ(R) 錠250mg) の薬理学的特性と臨床試験成績. 日薬理誌 144 : 294-304, 2014
  Medical*Online

• 5) 古野孝明, 高取優二, 宮家郁, 他 : 血液透析患者の腎性貧血に対するクエン酸第二鉄水和物の有効性の検討. 透析会誌 48 : 577-584, 2015

• 6) Daugirdas JT, Finn WF, Emmett M, et al : The phosphate binder equivalent dose. Semin Dial 24 : 41-49, 2011

• 7) 日本透析医学会 : 2008年版日本透析医学会慢性腎臓病患者における腎性貧血治療のガイドライン. 透析会誌 41 : 661-716, 2008

• 8) Bailie GR, Larkina M, Goodkin DA, et al : Variation in intravenous iron use internationally and over time. Nephrol Dial Transplant 28 : 2570-2579, 2013

• 9) Hasuike Y, Nonoguchi H, Tokuyama M, et al : Serum ferritin predicts prognosis in hemodialysis patients : the Nishinomiya study. Clin Exp Nephrol 14 : 349-355, 2010
  pubmed

• 10) Kuo KL, Hung SC, Lin YP, et al : Intravenous ferric chloride hexahydrate supplementation induced endothelial dysfunction and increased cardiovascular risk among hemodialysis patients. PLoS One 7 : e50295, 2012
  pubmed

• 11) Yokoyama K, Akiba T, Fukagawa M, et al : Long-term safety and efficacy of a novel iron-containing Phosphate binder, JTT-751, in patients receiving hemodialysis. J Ren Nutr 24 : 261-267, 2014
  pubmed

• 12) 三馬省二, 吉田克法, 佐々木憲二, 他 : 腎性貧血に対するエリスロポイエチン製剤治療維持期における鉄剤の投与方法に関する多施設共同研究. 臨床と研究 72 : 230-234, 1995

• 13) Dietzfelbinger H : Bioavailability of bi- and trivalent oral iron preparations. Investigations of iron absorption by postabsorption serum iron concentrations curves. Arzneimittelforschung 37 : 107-112, 1987
  pubmed

• 14) 齋藤宏 : 鉄代謝異常の臨床. 医薬ジャーナル社 56, 1998

• 15) 鳥居薬品株式会社 : リオナ(R) 錠250mg医薬品インタビューフォーム. 2014年5月 (改訂第2版), 2014

2. クエン酸第二鉄Dual Therapyへの期待と展望

P.75 掲載の参考文献

• 1) Bailie GR, Larkina M, Goodkin DA, et al : Variation in intravenous iron use internationally and over time : the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 28 : 2570-2579, 2013
  pubmed

• 2) Ferrari P, Kulkarni H, Dheda S, et al : Serum iron markers are inadequate for guiding iron repletion in chronic kidney disease. Clin J Am Soc Nephrol 6 : 77-83, 2011

• 3) Hamano T, Fujii N, Hayashi T, et al : Thresholds of iron markers for iron deficiency erythropoiesis-finding of the Japanese nationwide dialysis registry. Kidney Int 5 : S23-32, 2015

• 4) Morikami Y, Fujimori A, Okada S, et al : Comparison of 2-week versus 4-week dosing intervals of epoetin beta pegol on erythropoiesis and iron metabolism in hemodialysis patients. Ther Apher Dial 18 : 414-420, 2014
  pubmed

• 5) Rice L, Ruiz W, Driscoll T, et al : Neocytolysis on descent from altitude : anewly recognized mechanism for the control of red cell mass. Ann Intern Med 134 : 652-656, 2001

• 6) Brookhart MA, Freburger JK, Ellis AR, et al : Infection risk with bolus versus maintenance iron supplementation in hemodialysis patients. J Am Soc Nephrol 24 : 1151-1158, 2013

• 7) Pfeffer MA, Burdmann EA, Chen CY, et al : TREAT Investigators. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361 : 2019-2032, 2009

• 8) Swedberg K, Young JB, Anand IS, et al : RED-HF Committees ; RED-HF Investigators. Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med 368 : 1210-1219, 2013

• 9) Loo M, Beguin Y : The effect of recombinant human erythropoietin on platelet counts is strongly modulated by the adequacy of iron supply. Blood 93 : 3286-3293, 1999
  pubmed

• 10) Shovlin CL, Chamali B, Santhirapala V, et al : Ischaemic strokes in patients with pulmonary arteriovenous malformations and hereditary hemorrhagic telangiectasia : associations with iron deficiency and platelets. PLoS One 9 : e88812, 2014

• 11) Chang YL, Hung SH, Ling W, et al : Association between ischemic stroke and iron-deffciency anemia : apopulation-based study. PLoS One 8 : e82952, 2013

• 12) Kulnigg-Dabsch S, Schmid W, Howaldt S, et al : Iron deficiency generates secondary thrombocytosis and platelet activation in IBD : the randomized, controlled thrombo-VIT trial. Inflamm Bowel Dis 19 : 1609-1616, 2013

• 13) Anker SD, Comin Colet J, Filippatos G, et al : FAIR-HF Trial Investigators. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 361 : 2436-2448, 2009
  pubmed

• 14) Henry DH, Dahl NV, Auerbach MA : Thrombocytosis and venous thromboembolism in cancer patients with chemotherapy induced anemia may be related to ESA induced iron restricted erythropoiesis and reversed by administration of IV iron. Am J Hematol 87 : 308-310, 2012
  pubmed

• 15) 秋澤忠男, 下条文武, 西慎一, 他 : 保存期慢性腎臓病患者の腎機能保持 : ESAによる高いヘモグロビン目標値維持の効果. 腎と透析 76 : 119-128, 2014

• 16) Murray-Kolb LE, Beard JL : Iron treatment normalizes cognitive functioning in young women. Am J Clin Nutr 85 : 778-787, 2007

• 17) David V, Martin A, Isakova T, et al : Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production. Kidney Int 89 : 135-146, 2016

• 18) Yokoyama K, Hirakata H, Akiba T, et al : Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD. Clin J Am Soc Nephrol 9 : 543-552, 2014

• 19) Prats M, Font R, Garcia C, et al : Effect of ferric carboxymaltose on serum phosphate and C-terminal FGF231evels in non-dialysis chronic kidney disease patients : post-hoc analysis of a prospective study. BMC Nephrol 14 : 167, 2013

• 20) Toblli JE, Lombrafia A, Duarte P, et al : Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol 50 : 1657-1665, 2007
  pubmed

• 21) Ponikowski P, Filippatos G, Colet JC, et al : FAIR-HF Trial Investigators. The impact of intravenous ferric carboxymaltose on renal function : an analysis of the FAIR-HF study. Eur J Heart Fail 17 : 329-339, 2015
  pubmed

• 22) Ponikowski P, van Veldhuisen DJ, Comin-Colet J, et al : CONFIRM-HF Investigators. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J 36 : 657-668, 2015

• 23) Rodby R, Umanath K Niecestro R, et al : Phosphorus binding with ferric citrate is associated with fewer hospitalizations and reduced hospitalization costs. Expert Rev Pharmacoecon Outcomes Res 15 : 545-550, 2015
  pubmed

• 24) Agarwal R, Kusek JW, PapPas MK : A randomized trial of intravenous and oral iron in chronic kidney disease. Kidney Int 88 : 905-914, 2015
  pubmed

• 25) Verdon F, Burnand B, Stubi CL, et al : Iron supplementation for unexplained fatigue in non-anaemic women : double blind randomised placebo controlled trial. BMJ 326 : 1124, 2003
  pubmed

• 26) Krayenbuehl PA, Battegay E, Breymann C, et al : Intravenous iron for the treatment of fatigue in nonanemic, premenopausal women with low serum ferritin concentration. Blood 118 : 3222-3227, 2011
  pubmed

• 27) Sun ER, Chen CA, Ho G, et al : Iron and restless legs syndrome. Sleep 21 : 371-377, 1998
  pubmed

• 28) Silber MH, Richardson JW : Multiple blood donations associated with iron deficiency in patients with restless legs syndrome. Mayo Clin Proc 78 : 52-54, 2003
  pubmed

• 29) Sloand JA, Shelly MA, Feigin A, et al : A double-blind, placebo-controlled trial of intravenous iron dextran therapy in patients with ESRD and restless legs syndrome. Am J Kidney Dis 43 : 663-670, 2004

P.85 掲載の参考文献

• 1) Galy B, Ferring-Appel D, Becker C, et al : Iron Regulatory Proteins Control a Mucosal Block to Intestinal Iron Absorption. Cell Reports 3 : 844-857, 2013

• 2) Agarwal R, Kusek JW, PapPas MK : A randomized trial of intravenous and oral iron in chronic kidney disease. Kidney Int 88 : 905-914, 2015
  pubmed

• 3) Macdougall IC : Supplemental iron via dialysate : a novel mode of delivery for hemodialysis patients. Kidney Int 88 : 946-949, 2015
  pubmed

• 4) Kamei D, Akiba T : Coefficient of variation among ferritin measurement methods in hemodialysis and standard serum ferritin level. Kidney Int 88 : 197, 2015
  pubmed

P.93 掲載の参考文献

• 1) Block GA, Raggi P, Bellasi A, et al : Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 71 : 438-441, 2007
  pubmed

• 2) Chertow GM, Burke SK, Raggi P, et al : Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62 : 245-252, 2002
  pubmed

• 3) Shigematsu T : Multicenter prospective randomized, double-blind comparative study between lanthanum carbonate and calcium carbonate as phosphate binders in Japanese hemodialysis patients with hyperphosphatemia. Clin Nephrol 70 : 404-410, 2008

• 4) Goodman WG, Goldin J, Kuizon BD, et al : Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342 : 1478-1483, 2000

• 5) London GM, Marty C, Marchais SJ, et al : Terial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol 15 : 1943-1951, 2004

• 6) Behets GJ, Verberckmoes SC, Oste L, et al : Localization of lanthanum in bone of chronic renal failure rats after oral dosing with lanthanum carbonate. Kidney Int 67 : 1830-1836, 2005
  pubmed

• 7) Isakova T, Gutierrez OM, Chang Y, et al : Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol 20 : 388-396, 2009

• 8) Komaba H, Kakuta T, Suzuki H, et al : Survival advantage of lanthanum carbonate for hemodialysis patients with uncontrolled hyperphosphatemia. Nephrol Dial Transplant 30 : 107-114, 2015
  pubmed

• 9) Shinaberger CS, Greenland S, KoPPle JD, et al : Is controlling Phosphorus by decreasing dietary protein intake beneficial or harmful in persons with chronic kidney disease? Am J Clin Nutr 88 : 1511-1518, 2008

• 10) 角田裕俊, 他 : リン酸吸着ポリマー製剤を服用量の水と混同したときの水分吸収量膨潤の程度, 粘度および流動性に関する比較検討. 臨床透析 28 : 251-256, 2012

• 11) Hiratake J, Yasunaga C, Ootani A, et al : Peculiar histiocytic lesions with massive lanthanum deposition in dialysis patients treated with lanthanum carbonate. Am J Surg Pathol 39 : 767-771, 2015

• 12) Tonooka A, Uda S, Tanaka H, et al : Possibility of lanthanum absorption in the stomach. Clin Kidney J 8 : 572-575, 2015
  pubmed

• 13) Nakano C, Hamano T, Fujii N, et al : Combined Use of Vitamin D Status and FGF23 for Risk Stratification of Renal Outcome. Clin J Am Soc Nephrol 7 : 810-819, 2012
  pubmed

• 14) Levin A, Djurdjev O, Beaulieu M, et al : Variability and risk factors for kidney disease progression and death following attainment of stage 4 CKD in a referred cohort. Am J Kidney Dis 52 : 661-671, 2008

• 15) Voormolen N, Noordzij M, Grootendorst DC, et al : High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients. Nephrol Dial Transplant 22 : 2909-2916, 2007
  pubmed

• 16) Nagano N, Miyata S, Obana S, et al : Sevelamer hydrochloride, a phosphate binder, protects against deterioration of renal function in rats with progressive chronic renal insufficiency. Nephrol Dial Transplant 18 : 2014-2023, 2003

• 17) Farrow EG, Yu X, Summers LJ, et al : Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) pheno-type in fibroblast growth factor-23 (Fgf23) knock in mice. PNAS 108 : E1146-E1155, 2011

• 18) Coe LM, Madathil SV, Casu C, et al : FGF-23 is a negative regulator of prenatal and postnatal erythropoiesis. J Biol Chem 289 : 9795-9810, 2014

• 19) Yokoyama K, Hirakata H, Akiba T, et al : Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD. Clin J Am Soc Nephrol 9 : 543-552, 2014

• 20) Yamada S, Tokumoto M, Tatsumoto N, et al : Phosphate overload directly induces systemic inflammation and malnutrition as well as vascular calcification in uremia. Am J Physiol Renal Physiol 306 : F1418-1428, 2014
  pubmed

トピックス

P.99 掲載の参考文献

• 1) KDOQI : KDOQI clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease : 2007 update of hemoglobin target. Am J Kidney Dis 50 : 471-530, 2007

• 2) Umanath K, Jalal DI, Greco BA, et al : Ferric Citrate Reduces Intravenous Iron and Erythropoiesis-Stimulating Agent Use in ESRD. J Am Soc Nephrol 26 : 2578-2587, 2015

• 3) Conrad M Jr, Crosby WH : Intestinal mucosal mechanisms controlling iron absorption. Blood 22 : 406-415, 1963

• 4) Manis JG, Schachter D : Active transport of iron by intestine : effects of oral iron and pregnancy. Am J physiol 203 : 81-86, 1962

• 5) Wheby MS, Crosby WH : The gastrointestinal tract and iron absorption. Blood 22 : 416-428, 1963
  pubmed

• 6) Wheby MS, Jones LG, Crosby WH : Studies on iron absorption. Intestinal regulatory mechanisms. J Clin Invest 43 : 1433-1442, 1964

• 7) Eschbach JW, Cook JD, Scribner BH, et al : Iron balance in hemodialysis patients. Ann Intern Med 87 : 710-713, 1977
  pubmed

• 8) Cook JD, Lipschitz DA, Miles LE, et al : Serum ferritin as a measure of iron stores in normal subjects. Am J Clin Nutr 27 : 681-687, 1974
  pubmed

• 9) Gunshin H, Mackenzie B, Berger UV, et al : Cloning and characterization of a mammalian proton-coupled metal-ion transporter. Nature 388 : 482-488, 1997
  pubmed

• 10) Feder JN, Tsuchihashi Z, Irrinki A, et al : The hemochromatosis founder mutation in HLA-H disrupts beta2-microglobulin interaction and cell surface expression. J Biol Chem 272 : 14025-14028, 1997

• 11) Kawabata H, Yang R, Hirama T, et al : Molecular cloning of transferrin receptor 2. A new member of the transferrin receptor-like family. J Biol Chem 274 : 20826-20832, 1999
  pubmed

• 12) Lee PL, Beutler E, Rao SV, et al : Genetic abnormalities and juvenile hemochromatosis : mutations of the HJV gene encoding hemojuvelin. Blood 103 : 4669-4671, 2004

• 13) McKie AT, Barrow D, Latunde-Dada GO, et al : An iron-regulated ferric reductase associated with the absorption of dietary iron. Science 291 : 1755-1759, 2001
  pubmed

• 14) Donovan A, Brownlie A, Zhou Y, et al : Positional cloning of zebrafish ferroportin 1 identifies a conserved vertebrate iron exporter. Nature 403 : 776-781, 2000

• 15) Vulpe CD, Kuo YM, Murphy TL, et al : Hephaestin, a ceruloplasmin homologue implicated in intestinal iron transport, is defective in the sla mouse. Nat Genet 21 : 195-199, 1999
  pubmed

• 16) Rouault TA : The role of iron regulatory proteins in mammalian iron homeostasis and disease. Nat Chem Biol 2 : 406-414, 2006

• 17) Frazer DM, Wilkins SJ, Becker EM, et al : Arapid decrease in the expression of DMT-1 and Dcytb but not Iregl or hephaestin explains the mucosal block phenomenon of iron absorption. Gut 52 : 340-346, 2003
  pubmed

• 18) Poli M, Luscieti S, Gandini V, et al : Transferrin receptor 2 and HFE regulate furin expression via mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/Erk) signaling. Implications for transferrin-dependent hepcidin regulation. Haematologica 95 : 1832-1840, 2010
  pubmed

• 19) Enns CA, Ahmed R, Wang J, et al : Increased iron loading induces Bmp6 expression in the non-parenchymal cells of the liver independent of the BMP-signaling pathway. PLoS One 8 : e60534, 2013

• 20) Kautz L, Meynard D, Monnier A, et al : Iron regulates phosphorylation of Smad1/5/8 and gene expression of Bmp6, Smad7, Id1, and Atoh8 in the mouse liver. Blood 112 : 1503-1509, 2008
  pubmed

• 21) Arndt S, Maegdefrau U, Dorn C, et al : Iron-induced expression of bone morphogenic protein 6 in intestinal cells is the main regulator of hepatic hepcidin expression in vivo. Gastroenterology 138 : 372-382, 2010

• 22) Drakesmith H, Nemeth E, Ganz T : Ironing out Ferroportin. Cell Metab 22 : 777-787, 2015

• 23) Cao C, Thomas CE, Insogna KL, et al : Duodenal absorption and tissue utilization of dietary heme and nonheme iron differ in rats. J Nutr 144 : 1710-1717, 2014

• 24) Zimmermann MB, Troesch B, Biebinger R, et al : Plasma hepcidin is a modest predictor of dietary iron bioavailability in humans, whereas oral iron loading, measured by stable-isotoPe aPPea「ance culves, increases plasma hepcidin. Am J Clin Nutr 90 : 1280-1287, 2009

• 25) Ma S, Koshino Y, Yamamoto S, et al : Rapid Increase in Serum Iron Level After Oral Iron Intake as an Indicator of Duodenal Iron Absorption and Inverse Regulation of Iron Absorption by Hepcidin Expression. J Kanazawa Med Univers 41, 2016

P.103 掲載の参考文献

• 1) Wolf M, White KE : Coupling fibroblast growth factor 23 production and cleavage : iron deficiency, rickets, and kidney disease. Curr Opin Nephrol Hypertens 23 : 411-419, 2014

• 2) Econs MJ, McEnery PT : Autosomal dominant hypophosphatemic rickets/osteomalacia : clinical characterization of a novel renal phosphate-wasting disorder. J Clin Endocrinol Metab 82 : 674-681, 1997

• 3) Imel EA, Peacock M, Gray AK, et al : Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans. J Clin Endocrinol Metab 96 : 3541-3549, 2011
  pubmed

• 4) Farrow EG, Yu X, Summers LJ, et al : Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice. Proc Natl Acad Sci U S A 108 : E1146-1155, 2011

• 5) Imel EA, Liu Z, McQueen AK, et al : Serum fibroblast growth factor 23, serum iron and bone mineral density in premenopausal women. Bone 86 : 98-105, 2016

• 6) Bozentowicz-Wikarek M, Kocelak P, Owczarek A, et al : Plasma fibroblast growth factor 23 concentration and iron status. Does the relationship exist in the elderly population? Clin Biochem 48 : 431-436, 2015

• 7) Smith ER, Cai MM, McMahon LP, et al : Biological variability of plasma intact and Cterminal FGF23 measurements. J Clin Endocrinol Metab 97 : 3357-3365, 2012

• 8) Deger SM, Erten Y, Pasaoglu OT, et al : The effects of iron on FGF23-mediated Ca-P metabolism in CKD patients. Clin Exp Nephrol 17 : 416-423, 2013

• 9) Shimizu Y, Tada Y, Yamauchi M, et al : Hypophosphatemia induced by intravenous administration of saccharated ferric oxide : another form of FGF23-related hypophosphatemia. Bone 45 : 814-816, 2009
  pubmed

• 10) Takeda Y, Komaba H, Goto S, et al : Effect of intravenous saccharated ferric oxide on serum FGF23 and mineral metabolism in hemodialysis patients. Am J Nephrol 33 : 421-426, 2011

• 11) Wolf M, Koch TA, Bregman DB : Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. J Bone Miner Res 28 : 1793-1803, 2013
  pubmed

• 12) Yokoyama K, Hirakata H, Akiba T, et al : Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD. Clin J Am Soc Nephrol 9 : 543-552, 2014

• 13) Iguchi A, Kazama JJ, Yamamoto S, et al : Administration of Ferric Citrate Hydrate Decreases Circulating FGF23 Levels Independently of Serum Phosphate Levels in Hemodialysis Patients with Iron Deficiency. Nephron 131 : 161-166, 2015

• 14) di Giuseppe R, KUhn T, Hirche F, et al : Potential Predictors of Plasma Fibroblast Growth Factor 23 Concentrations : Cross-Sectional Analysis in the EPIC-Germany Study. PLoS One 10 : e0133580, 2015

• 15) Coe LM, Madathil SV, Casu C, et al : FGF-23 is a negative regulator of prenatal and postnatal erythropoiesis. J Biol Chem 289 : 9795-810, 2014
  pubmed

• 16) Tsai MH, Leu JG, Fang YW, et al : High Fibroblast Growth Factor 23 Levels Associated With Low Hemoglobin Levels in Patients With Chronic Kidney Disease Stages 3 and 4. Medicine (Baltimore) 95 : e3049, 2016

• 17) David V, Martin A, Isakova T, et al : Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production. Kidney Int 89 : 135-146, 2016

P.108 掲載の参考文献

• 1) Herman J. C. Berendsen : データ・誤差解析の基礎. 林茂雄, 馬場凉訳, 東京化学同人 : 東京, 2013

• 2) John R. Taylor : 計測における誤差解析入門. 林茂雄, 馬場凉訳, 東京化学同人 : 東京, 2000

• 3) 日本医師会 : 第48回臨床検査精度管理調査結果報告書. 平成26年度

• 4) Kliger AS, Foley RN, Goldfarb DS, et al : KDOQI US commentary on the 2012 KDIGO Clinical Practice Guideline for Anemia in CKD. Am J Kidney Dis 62 : 849-859, 2013
  pubmed

• 5) McMurray JJB, Parfrey PS, Adamson JW, et al : Kidney Disease : Improving global Outcomes (KDIGO) Anemia Work Group : KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl 2 : 279-335, 2012

• 6) Macginley R, Walker R, Irving M : KHACARI Guideline : use of iron in chronic kidney disease patients. Nephrology (Carlton) 18 : 747-749, 2013
  pubmed

• 7) Locatelli F, Barany P, Covic A, et al : Kidney Disease : Improving Global Outcomes guidelines on anaemia management in chrollic kidney disease : aEuropean Renal Best Practice position statement. Nephrol Dial Transplant 28 : 1346-1359, 2013

• 8) Madore F, White CT, Foley RN, et al : Canadian Society of Nephrology. Clinical practice guidelines for assessment and management of iron deficiency. Kidney Int Suppl 110 : S7-S11, 2008

• 9) Tsubakihara Y, Nishi S, Akiba T, et al : 2008 Japanese Society for Dialysis Therapy : guidelines for renal anemia in chronic kidney disease. Ther Apher Dial 14 : 240-275, 2010
  pubmed

• 10) 日本透析医学会ガイドライン作成委員会 : 2015年版慢性腎臓病患者における腎性貧血治療のガイドライン. 透析会誌 49 : 89-158, 2016